Consensus ImpediMed Limited

Equities

Market Closed - Australian S.E. Other stock markets 02:10:59 2024-05-14 am EDT			5-day change	1st Jan Change
0.08 ^AUD	+1.27%		-1.23%	-44.83%

Apr. 30	ImpediMed's Qaurterly Revenue Rises in Fiscal Q3; Shares Fall 8%	MT
Apr. 30	Transcript : ImpediMed Limited, Q3 2024 Earnings Call, Apr 30, 2024

6b8628bf6a3.CodqDOCs69In62ljw7t5gWJMeKhSv2LcRAa47WJevGc.bMEnNLnfseBRii8z8I0xxQolGesHxhCPHG3ywFVzzjJE0gI_ldyqkWPbIA~f5bf1a22dcfadbcc96a5ec5c10c9b975

Ord Minnett Starts ImpediMed at Speculative Buy, Price Target is AU$0.16	Apr. 16	MT
ImpediMed Limited Announces Current Data Support Early Detection and Intervention to Reduce Rates of Breast Cancer Related Lymphedema	22-10-26	CI

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.08 AUD

Average target price

0.1753 AUD

Spread / Average Target

+119.15%

High Price Target

0.2013 AUD

Spread / Highest target

+151.62%

Low Price Target

0.14 AUD

Spread / Lowest Target

+75.00%

Ord Minnet

Trading Rating

Investor Rating

ESG Refinitiv